Cell-free tumor DNA for cancer monitoring

Size: px
Start display at page:

Download "Cell-free tumor DNA for cancer monitoring"

Transcription

1 Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the pre-analytic and standardization challenges associated with ctdna 3. Summarize the clinical utility of ctdna through several clinical examples Speaker has no financial disclosures Outline Defining the jargon Definitions and pre-analytic considerations for circulating tumor DNA CTC, circulating tumor cells Intact tumor cells in the bloodstream CTC cell-free or circulating DNA Clinical examples: ctdna detection, monitoring treatment response, acquired resistance cfdna, cell-free DNA DNA fragments circulating in the bloodstream ctdna, circulating tumor DNA Tumor-derived fraction of cfdna Image: Williams SCP. PNAS 2013;110:4861 Images: Nat Med 2008;14:914, Nat Biotechnol 2014;32:441 1

2 Timeline of discovery and recognition of the significance of cfdna in oncology Current clinical applications of cell-free DNA 1948: Mandel and Metais initial description cfdna 1977: Leon et al reported higher cfdna blood of cancer patients 1990s: multiple types of alterations in cfdna 1965: Bendich et al ctdna involved in oncogenesis 1989: Stroun et al showed mutant cfdna in plasma NIPT Somatic Images: NY Times June 11, 2015, What is a liquid biopsy? ctdna particulars CTCs cfdna ctdna cfdna concentrations vary in healthy, non-pregnant individuals ng/ml Trace amounts in plasma DNA fragments released are small bp Short plasma half life Less than 2 hours Exosomes Modified from Speicher MR and Pantel K. Nat Biotechnol 2014;32:441 2

3 ctdna release mechanisms from tumor cells Secretion Apoptosis Necrosis Biologic factors affect ctdna concentrations Tumor size / stage Tumor localization Tumor vascularity Tumor metastasis Mucinous features Treatment (radiation, surgery, chemotherapy) CTC lysis Modified from Diaz LA and Bardelli A. J Clin Oncol 2014;32:579 Tissue biopsy Gold standard Sample stability Archived bank +/- higher concentration of tumor cells Liquid biopsy: ctdna Less invasive Serial monitoring Preservation much less damaging Molecular proxy of overall disease Numerous pre-analytical variables can confound ctdna results Matrix Collection & processing Sample storage Sample thawing DNA isolation Storage of DNA Quantification Analysis 3

4 Variants come in all shapes and sizes Size (bp) Variant type Example 1 Substitution, SNV BRAF p.v600e Several types of variants are poorly (or not) detected by current methods, pipelines Size (bp) 1 Variant type Substitution, SNV <15 Small indel EGFR exon 19 deletions <15 Small indel <500 Med indel FLT3 ITD, internal tandem duplication <500 Med indel >500 Large indel Li-Fraumeni syndrome exon deletion in TP53 >500 Large indel >1000 Copy number variant MET amplification >1000 Copy number alteration Variable Structural variants eg, translocation EML4-ALK Variable Structural variants eg, translocation Different detection methods/platforms offer different advantages and limitations Outline Method Sens. Mutations Mut per assay Mut info required Real-time/digital qpcr >0.1% Known SNVs 1 Yes Targeted enriched seq >0.01% Known SNVs, indels ~100 Yes Targeted seq >0.5-1% Known SNVs, indels, structural variants, copy number variants >1000 No Definitions and pre-analytic considerations for circulating tumor DNA Clinical examples: ctdna detection, monitoring treatment response, acquired resistance Image: Williams SCP. PNAS 2013;110:4861 4

5 Potential clinical applications of ctdna Potential clinical applications of ctdna Detection Detection CNS tumors Resistance Heterogeneity, tumor dynamics Resistance NSCLC Heterogeneity, tumor dynamics MRD detection Tx response MRD detection Tx response CRC Frequency of cases with detectable ctdna (%) ctdna detection varies among tumor types N=163 patients Advanced disease Metastatic Primary gliomas ddpcr method Fraction of patients with detectable ctdna correlates with tumor stage Frequency of cases with detectable ctdna (%) N=223 patients Localized and metastatic disease Breast Colon Pancreas Gastroesophageal Bettegowda C, et al., Sci Transl Med 2014;226 I II III IV Tumor stage Bettegowda C, et al., Sci Transl Med 2014;226 5

6 Trend that ctdna concentration increases with tumor size Monitoring recurrence-free survival in mcrc: ctdna better predictor than CEA N=9 patients NSCLC stages I-IV Tumor volume measured by CT or PET-CT Deep sequencing method CAPP-Seq N=18 patients Metastatic CRC Curative surgical resection Newman AM, et al., Nat Med 2014;20:548 Diehl F, et al., Nat Med 2008;14:985 Acquired resistance to EGFR inhibitors in ctdna from mcrc patients ctdna detection in CNS tumors: cfdna concentration is higher in plasma than CSF N=24 patients All acquired resistance to EGFR blockade 96% patients Ras mutation 70 mutations present in plasma post-tki treatment None present pre-tx Bettegowda C, et al., Sci Transl Med 2014;226 Pan W, et al., Clin Chem 2015;61:514 6

7 ctdna detection in CNS tumors: tumor mutations more detectable in CSF CNS tumors may be more amenable to ctdna detection in CSF N=7 patients Detected ctdna in 6/7 CSF samples Detected ctdna in 3/7 (+/-1) plasma samples Both targeted NGS and ddpcr Pan W, et al., Clin Chem 2015;61:514 N=12 patients 4 GBM 8 brain mets from lung or breast primary Representative example from a patient with GBM Both targeted NGS and ddpcr De Mattos-Arruda L, et al., Nat Commun 2015;10:8839 Resistance: ctdna detection of EGFR T790M in lung cancer N=117 patients with acquired TKI resistance 117 NSCLC patients ctdna measured before, after EGFR-TKI progression (PD) Patients grouped every 2 months relative to 1 st PD Zheng D, et al., Sci Rep 2016;6:

8 Proof of principle: OncoPlex ctdna Tissue Comprehensive somatic sequencing assay Currently v5 contains 262 cancer-related genes Detects SNVs, indels, structural rearrangements, copy number alterations Type of mutation VAF, variant allele frequency SNV 0.29* Frameshift insertion 0.18 ctdna SNV 0.18 SNV 0.17 Pritchard CC, et al., J Mol Diagn 2014;16:56 Barriers to clinical implementation of ctdna Summary Lack of standardization regarding pre-analytic factors Specimen sampling, processing, storage ctdna generally associated with high specificity, but lower sensitivity Single target assays can not identify whether ctdna is present False negatives can have a significant clinical impact Challenging to prospectively collect plasma in clinical practice in conjunction with tumor biopsies Analytical methods and their sensitivities highly variable Proof of principle data is promising Currently lack prospective, large scale studies that establish clinical value >15 ongoing clinical trials evaluating ctdna in solid tumors with therapeutic intervention 8

9 ctdna: hype or hope? Acknowledgements Francis Collins at the completion of the HGP in 2006 The enthusiasm cycle for new technology John Tait Colin Pritchard Mallory Beightol Eric Konnick Steve Salipante Brian Shirts David Wu Collins F, Nature 2006;S1:9-12 9

NGS in tissue and liquid biopsy

NGS in tissue and liquid biopsy NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences

More information

Disclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath

Disclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant

More information

Introduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory

Introduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free

More information

Circulating Tumor DNA in GIST and its Implications on Treatment

Circulating Tumor DNA in GIST and its Implications on Treatment Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna

More information

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation

More information

Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~

Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ 16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of

More information

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity

More information

Pros and cons of liquid biopsy: Ready to replace tissue?

Pros and cons of liquid biopsy: Ready to replace tissue? Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:

More information

Qué hemos aprendido hasta hoy? What have we learned so far?

Qué hemos aprendido hasta hoy? What have we learned so far? Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;

More information

Liquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director

Liquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:

More information

Biopsia Líquida: Oncología en Tiempo Real. Federico Rojo Fundación Jiménez Díaz

Biopsia Líquida: Oncología en Tiempo Real. Federico Rojo Fundación Jiménez Díaz Biopsia Líquida: Oncología en Tiempo Real Federico Rojo Fundación Jiménez Díaz Liquid Biopsy in Cancer Liquid Biopsy in Cancer Publication Date: April 5, 2016 Blood Tests replace Surgical Biopsies to create

More information

FUTURE PERSPECTIVES OF CIRCULATING TUMOR DNA IN COLORECTAL CANCER

FUTURE PERSPECTIVES OF CIRCULATING TUMOR DNA IN COLORECTAL CANCER FUTURE PERSPECTIVES OF CIRCULATING TUMOR DNA IN COLORECTAL CANCER C. NADAL 1-3, T. WINDER 4, A. GERGER 5-6, D. TOUGERON 7-8 SELECTED HIGHLIGHTS 1 Medical Oncology Department, Institut Clínic de Malalties

More information

Information Guide - August Liquid Biopsies for Cancer Management

Information Guide - August Liquid Biopsies for Cancer Management Information Guide - August 2017 Liquid Biopsies for Cancer Management INFORMATION GUIDE - AUGUST 2017 Liquid Biopsies for Cancer Management CIRCULATING TUMOR DNA IN BLOOD AS A LIQUID BIOPSY FOR CANCER

More information

Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015

Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015 Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of

More information

CTC in clinical studies: Latest reports on GI cancers

CTC in clinical studies: Latest reports on GI cancers CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis

More information

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients

The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM

More information

MET skipping mutation, EGFR

MET skipping mutation, EGFR New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM

More information

Personalized oncology: the potential for tissue and cell-free DNA

Personalized oncology: the potential for tissue and cell-free DNA Open Citation: J Med Discov (2016); 1(1):jmd16005; doi:10.24262/jmd.1.1.16005 Commentary Personalized oncology: the potential for tissue and cell-free DNA biopsies to capture tumor heterogeneity Young

More information

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect

More information

Liquid biopsy in lung cancer: The EGFR paradigm

Liquid biopsy in lung cancer: The EGFR paradigm Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships

More information

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%

More information

QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing

QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy

More information

Round Table: Tissue Biopsy versus Liquid Biopsy. César A. Rodríguez Hospital Universitario de Salamanca-IBSAL

Round Table: Tissue Biopsy versus Liquid Biopsy. César A. Rodríguez Hospital Universitario de Salamanca-IBSAL Round Table: Tissue Biopsy versus Liquid Biopsy César A. Rodríguez Hospital Universitario de Salamanca-IBSAL Introduction Classic Advantages of liquid biopsy collection over standard biopsy Standard biopsy

More information

Thor Nilsen NeoGeneStar LLC January 22, 2015

Thor Nilsen NeoGeneStar LLC January 22, 2015 Thor Nilsen NeoGeneStar LLC January 22, 2015 NeoGeneStar TM I. Liquid biopsy using circulating cell-free DNA: Cancer diagnostics Prenatal diagnostics Other disease states II. NeoGeneStar TM cell-free DNA

More information

Circulating tumour DNA in breast cancer. Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho

Circulating tumour DNA in breast cancer. Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho Circulating tumour DNA in breast cancer Kathleen Burke, PhD Bioinformatics Postdoctoral Fellow Laboratory of Dr. Jorge Reis-Filho Conflicts of Interest I have no financial relationships to disclose I will

More information

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Liquid biopsies come of age: towards implementation of circulating tumour DNA Liquid biopsies come of age: towards implementation of circulating tumour DNA Jonathan C. M. Wan 1,2, Charles Massie 1,2, Javier Garcia-Corbacho 3, Florent Mouliere 1,2, James D. Brenton 1,2, Carlos Caldas

More information

Molecular Testing in Lung Cancer

Molecular Testing in Lung Cancer Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans

More information

ECMC cfdna consensus meeting

ECMC cfdna consensus meeting ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients

More information

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Aaron M Newman1,2,7, Scott V Bratman1,3,7, Jacqueline To3, Jacob F Wynne3, Neville C W Eclov3, Leslie A Modlin3,

More information

Liquid biopsy: the experience of real life case studies

Liquid biopsy: the experience of real life case studies Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal

More information

ccfdna Webinar Series: The Basics and Beyond

ccfdna Webinar Series: The Basics and Beyond ccfdna Webinar Series: The Basics and Beyond Part I Maxwell RSC ccfdna Plasma Kit and Maxwell RSC instrument are For Research Use Only. Not for Use in Diagnostic Procedures. Introduction to Circulating,

More information

Celvrij DNA: nieuwe diagnostische mogelijkheden

Celvrij DNA: nieuwe diagnostische mogelijkheden Celvrij DNA: nieuwe diagnostische mogelijkheden Dr. Helena Devos - Hematologie voor de huisarts 2.0 9 februari 2019 Content What is cell free DNA? Clinical applications: Prenatal: NIPT In oncology/hematology:

More information

DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA

DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias

More information

OverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA

OverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

Integrated platform for liquid biopsy-based personalized cancer medicine

Integrated platform for liquid biopsy-based personalized cancer medicine Integrated platform for liquid biopsy-based personalized cancer medicine Dr. Bernhard Polzer Fraunhofer ITEM-Regensburg Personalized Tumor Therapy Personalized cancer therapy Primary tumor single tumor

More information

Enterprise Interest No

Enterprise Interest No Enterprise Interest No SY-05 Pulmonary Pathology: Options for targeted therapy in lung cancer Liquid biopsy in thoracic oncology Where are we now? Paul Hofman Laboratory of Clinical and Experimental Pathology

More information

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie

Advances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et

More information

LUNG CANCER Searching early biomarkers in blood

LUNG CANCER Searching early biomarkers in blood LUNG CANCER Searching early biomarkers in blood Eloisa Jantus Lewintre Laboratorio Oncología Molecular- FIHGUV Servicio Oncología Médica, CHGUV Dpto Biotecnología- Universitat Politècnica de València CIBERONC,

More information

NGS for Cancer Predisposition

NGS for Cancer Predisposition NGS for Cancer Predisposition Colin Pritchard MD, PhD University of Washington Dept. of Lab Medicine AMP Companion Society Meeting USCAP Boston March 22, 2015 Disclosures I am an employee of the University

More information

Diagnostic with alternative sample types (liquid biopsy)

Diagnostic with alternative sample types (liquid biopsy) MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology

More information

A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis

A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown

More information

Case Studies. Ravi Salgia, MD, PhD

Case Studies. Ravi Salgia, MD, PhD Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives

More information

Transforming Oncology With Precision Medicine Solutions. Company Overview January 2017

Transforming Oncology With Precision Medicine Solutions. Company Overview January 2017 Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 FORWARD-LOOKING STATEMENTS Statements in this presentation about the Company's expectations, applications of its technology,

More information

PRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.

PRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna. PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular

More information

Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D

Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Department of Radiation Oncology University of Florida College of Medicine Outline Objective

More information

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes

More information

Comprehensive Analyses of Circulating Cell- Free Tumor DNA

Comprehensive Analyses of Circulating Cell- Free Tumor DNA Comprehensive Analyses of Circulating Cell- Free Tumor DNA Boston, MA June 28th, 2016 Derek Murphy, Ph.D. Scientist, Research and Development Personal Genome Diagnostics Acquisition of Somatic Alterations

More information

Role of liquid biopsy in lung cancer 20/10/2017

Role of liquid biopsy in lung cancer 20/10/2017 Role of liquid biopsy in lung cancer 20/10/2017 Overview of Seminar Background Concept of liquid biopsy Different Biological Components of Liquid Biopsy Various samples used in liquid biopsy EGFR mutation

More information

Next generation diagnostics Bringing high-throughput sequencing into clinical application

Next generation diagnostics Bringing high-throughput sequencing into clinical application Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no

More information

Aplicaciones de la biopsia líquida en Oncología

Aplicaciones de la biopsia líquida en Oncología Aplicaciones de la biopsia líquida en Oncología Congreso Nacional del Laboratorio Clínico 2017 Emilio Alba UGCI Oncología Médica. Hospital Universitario Regional y Virgen de la Victoria Departamento de

More information

Youngnam Cho. National Cancer Center Biomarker Branch

Youngnam Cho. National Cancer Center Biomarker Branch Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY

More information

Development of Circulating Tumor DNA

Development of Circulating Tumor DNA Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational

More information

La biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome

La biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome La biopsia liquida dei tumori: il viaggio Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome Must Know Necessary Travel Tips There is lack of drugs to treat all the

More information

Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018

Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Consensus statement between CM-Path, CRUK and the PHG Foundation following on from the Liquid Biopsy workshop on the 8th March 2018 Summary: This document follows on from the findings of the CM-Path The

More information

MET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine

MET as a novel treatment target- the story of the sleeping beauty. Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine MET as a novel treatment target- the story of the sleeping beauty Balazs Halmos M.D. Montefiore Medical Center/Albert Einstein College of Medicine MET as a novel treatment target MET as an oncogene MET

More information

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy

More information

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:

More information

Robert Beer

Robert Beer Robert Beer Robert.beer@wales.nhs.uk All Wales Medical Genetics Service Genetic Technologist Training Day 22 nd November 2017 Contents Stratified Medicine NHS EGFR Diagnostic Testing Services Cell free

More information

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB

More information

CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases

CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases Adriana Muniz 1, Mariko Matsutani 1, Karena Kosco 1, John Spinosa 1, Cecile

More information

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018 Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as

More information

Lukas Bubendorf Pathologie. Liquid biopsies

Lukas Bubendorf Pathologie. Liquid biopsies Lukas Bubendorf Pathologie Liquid biopsies Liquid biopsies 1. Circulating cell-free tumor-dna (ctdna) 2. Circulating tumor cells (CTC) Source: Sysmex CTCs ctdna ctrna exosomes Quantification Protein RNA

More information

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17 Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic

More information

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical

More information

Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017

Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers. Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 Drug Resistance in ALK- and ROS1-Rearranged Lung Cancers Alice T. Shaw, MD PhD Director, Center for Thoracic Cancers September 16, 2017 ALK and ROS1 are Related Tyrosine Kinases, and Both are Targeted

More information

Supplementary Tables. Supplementary Figures

Supplementary Tables. Supplementary Figures Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample

More information

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff 5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late

More information

Reporting TP53 gene analysis results in CLL

Reporting TP53 gene analysis results in CLL Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review

More information

1/23/2017. Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical School

1/23/2017. Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical School Application of Cytologic Techniques to Circulating Tumor Cell Specimens Alarice Lowe, MD Assistant Professor of Pathology Director, Circulating Tumor Cell Lab Brigham and Women s Hospital Harvard Medical

More information

ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria

ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,

More information

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011? Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations

More information

Disclosures Genomic testing in lung cancer

Disclosures Genomic testing in lung cancer Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing

More information

MP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)

MP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular

More information

Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia

Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head

More information

Products for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma

Products for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery

More information

Analysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer

Analysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer Accepted Manuscript Analysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer David S. Schrump, MD, MBA, Julie A. Hong, MS PII: S0022-5223(18)30295-2 DOI: 10.1016/j.jtcvs.2018.01.060

More information

Agenda. What is a Liquid Biopsy? Biocept technology. Concordance With Tissue. Clinical Applications. Billing and Reimbursement.

Agenda. What is a Liquid Biopsy? Biocept technology. Concordance With Tissue. Clinical Applications. Billing and Reimbursement. Agenda What is a Liquid Biopsy? Biocept technology Concordance With Tissue Clinical Applications Billing and Reimbursement Recap & Questions 1 Targets of Tumor Found in Liquid Biopsy 1 Eric Topol, Professor

More information

What do liquid biopsies offer us for breast cancer patients?

What do liquid biopsies offer us for breast cancer patients? What do liquid biopsies offer us for breast cancer patients? Isaac Garcia-Murillas Breast Cancer Now Research Centre, The institute of Cancer Research, London, UK Molecular Analysis of breast cancer Invasive

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

Evolution of Pathology

Evolution of Pathology 1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy

More information

CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES

CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli

More information

EGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester

EGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester EGFR ctdna Testing Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester ctdna & EGFR Testing in NSCLC EGFR ctdna testing Non-invasive - patients too sick/biopsy or cytology

More information

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:

More information

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018 CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines

More information

Role of liquid biopsies and circulating tumor DNA. Pierre Laurent-Puig European Georges Pompidou Hospital Paris Descartes University

Role of liquid biopsies and circulating tumor DNA. Pierre Laurent-Puig European Georges Pompidou Hospital Paris Descartes University Role of liquid biopsies and circulating tumor DNA Pierre Laurent-Puig European Georges Pompidou Hospital Paris Descartes University DISCLOSURE AMGEN ASTRAZENECA BIOCARTIS BOERINGHER INGELHEIM INTEGRAGEN

More information

Detection of low-frequent mitochondrial DNA variants using SMRT sequencing

Detection of low-frequent mitochondrial DNA variants using SMRT sequencing Detection of low-frequent mitochondrial DNA variants using SMRT sequencing Marjolein J.A. Weerts SMRT Leiden 2018 June 13 Content Mitochondrial DNA & liquid biopsy in oncology Pitfalls when studying human

More information

Personalized Genetics

Personalized Genetics Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not

More information

The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific

The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific Affairs,Sysmex 2 OncoBEAM liquid biopsy: circulating tumor DNA (ctdna)

More information

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why

More information

The OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice

The OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice The OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice Sysmex Inostics Dr. Friederike Lehmann Head of CRO Marketing Sysmex Corporation Kobe 2 Sysmex Corporation

More information

Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mcrc

Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mcrc Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mcrc Alberto Bardelli Candiolo Cancer Center IRCCs University of Torino - Medical School Disclosures Horizon discovery Biocartis

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Page 1 of 36 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Circulating Tumor DNA

More information

EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide

EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide The information in this pocket guide is intended as reference material and should not replace clinical judgment or updated

More information

Anatomic Molecular Pathology: An Emerging Field

Anatomic Molecular Pathology: An Emerging Field Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty

More information

Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC

Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Translational Gastrointestinal Oncology Remond Fijneman r.fijneman@nki.nl Department of Pathology, Amsterdam, NL Wat is de potentiële waarde van ctdna?

More information

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell

More information

Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)

Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield

More information

Introduction to liquid biopsy in a Specialized Cancer Center

Introduction to liquid biopsy in a Specialized Cancer Center Introduction to liquid biopsy in a Specialized Cancer Center Dr. Antonio Cubillo Head, Medical OncologyDepartment HM-CIOCC In collaboration with OUTLINE Need Liquid Biopsy: Definition and techniques Sensitivity

More information

Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA

Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA Lucy Xu, Ph.D. Associate Director Clinical Biomarker Research Eisai Inc. Woodcliff Lake, NJ Precision LBx Summit San Diego, CA

More information